NCI Collaborator definition

NCI Collaborator means the pharmaceutical or biotechnology company having a CRADA with NCI to provide Formulary Agent(s) to the NCI Formulary, as listed above.
Sample 1Sample 2Sample 3
NCI Collaborator means a company having a collaborative agreement with the NCI or a Network Group to provide Agent(s) for use in association with the Protocol(s). This includes agreements with NCI and/or directly with a Clinical Trial Network/Clinical Research Site.
Sample 1Sample 2
NCI Collaborator means a company that made available its Agent(s) for use in association with the Protocol(s). This includes agreements with NCI and/or directly with a Clinical Trial Network/Clinical Research Site. When the NCI Clinical Trial Network Protocol is also a PACT-Funded Trial Protocol, the NCI Collaborator will also be a PACT Collaborator.
Sample 1Sample 2

Examples of NCI Collaborator in a sentence

  • Approved Investigator will be responsible for submitting the Formulary Protocol to xxxxxxxxxxxxxx.xxx within twenty-one (21) days of initiating patient enrollment, and providing the results reporting as required, it being understood that no such submission will be made until after the Formulary Protocol is approved by NCI Collaborator.

  • Approved Investigator will submit, or arrange for submission of, the Formulary Protocol to all appropriate IRBs, and ensure that the IRBs are notified of the role of NCI Collaborator in providing the Formulary Agent(s) for the research by including NCI Formulary standard protocol language into the final Formulary Protocol.

  • Manuscripts to be submitted for publication and proposed abstracts or presentations by Approved Investigators will be sent to NCI’s Regulatory Affairs Branch at NCI CTEP Publications for forwarding to NCI Collaborator for review as soon as they are received and in compliance with the timelines outlined above.

  • Unless prohibited by law from doing so, Institution agrees to hold the Government and NCI Collaborator harmless and to indemnify the Government and Collaborator for all liabilities, demands, damages, expenses and losses arising out of Institution's use for any purpose of the Formulary Agent(s).

  • Approved Investigator will also include language in the informed consent stating that the NCI Collaborator will have access to all data, including raw data, from the Protocol for regulatory purposes.

  • NCI and NCI Collaborator make no representations that the use of the Formulary Agent(s) will not infringe any patent or proprietary rights of third parties.

  • An initial draft version of the Formulary Protocol must be submitted to the NCI at the same time it is provided to NCI Collaborator for Formulary Agent forecasting purposes.

  • Integrating biodiversity conservation into the capacity building process further promotes the long-term stability of forests and helps to mitigate the negative impacts of climate change.

  • Institution and Approved Investigator further agree to make sure the informed consent form includes language providing the NCI and the NCI Collaborator with access to all data, including raw data and case report forms for regulatory purposes.

  • If Approved Investigator and/or Institution are unwilling to delay the publication or presentation, Approved Investigator/Institution will remove from the publication or presentation the information which NCI Collaborator has specified it reasonably believes would jeopardize its intellectual property interests.


More Definitions of NCI Collaborator

NCI Collaborator means a company that made available its Agent(s) for use in association with the NCI/CTEP-approved Protocol(s).
Sample 1

Related to NCI Collaborator

  • Collaborator An individual who is not under the direct supervision of the PI (e.g., not a member of the PI’s laboratory) who assists with the PI’s research project involving controlled-access data subject to the NIH GDS Policy. Internal collaborators are employees of the Requester and work at the same location/campus as the PI. External collaborators are not employees of the Requester and/or do not work at the same location as the PI, and consequently must be independently approved to access controlled-access data subject to the NIH GDS Policy.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Research Program Term has the meaning set forth in Section 2.2.

  • Collaboration Technology means all Collaboration Patents and Collaboration Know-How.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • BMS means the Company, all related companies, affiliates, subsidiaries, parents, successors, assigns and all organizations acquired by the foregoing.

  • Licensor Technology means the Licensor Patents, the Licensor Know-How, Licensor Materials, Product IP, and Licensor’s rights in the Program IP and Joint Patents.

  • Third Party Technology means all Intellectual Property and products owned by third parties and licensed pursuant to Third Party Licenses.

  • Licensee Technology means the Licensee Know-How and Licensee Patents.

  • GSK will have the meaning set forth in the Preamble.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Research Program has the meaning set forth in Section 2.1.

  • Licensed Products means tangible materials which, in the course of manufacture, use, sale, or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

  • Program Technology means Program Know-How and Program Patents.

  • Licensed Compound means (a) 3,4-Diaminopyridine, the chemical structure of which is set forth on Exhibit B-2; and (b) any derivatives, isomers, metabolites, prodrugs, acid forms, base forms, salt forms, or modified versions of such compound in (a).

  • Collaboration Term has the meaning set forth in Section 2.2.

  • Program Patent Rights means all Patent Rights that claim or cover patentable Program Know-How, including any Program-Specific Patent Rights.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Joint Patent Rights means all Patent Rights claiming a Joint Invention.

  • Sublicensees as used herein in either singular or plural shall mean any person or entity other than an AFFILIATED COMPANY to which Company has granted a sublicense under this Agreement.

  • Research Materials means all tangible materials other than Subject Data first produced in the performance of this CRADA.

  • Collaboration has the meaning set forth in Section 2.1.

  • Joint Technology means Joint Inventions and Joint Patents.